Table 1.
Patient, tumor, and treatment characteristics
| Characteristics | Number (%) |
|---|---|
| Age (median) | 8 years (range 4–24 years) |
| Gender | |
| Male | 13 (39) |
| Female | 20 (61) |
| Tumor volume (median) | 59 cc (range 12–174 cc) |
| Contrast enhancement | |
| Yes | 24 (73) |
| No | 9 (27) |
| Treatment at progression | |
| Chemotherapy only | 18 (55) |
| Chemotherapy and re-irradiation | 15 (45) |
| Re-irradiation dose (median) | 23.4 Gy (range 19.8–36 Gy) |
| Re-irradiation regimens | |
| 36 Gy in 20 fractions | 1 (7) |
| 30 Gy in 12 fractions | 3 (20) |
| 24 Gy in 12 fractions | 4 (26) |
| 20 Gy in 10 fractions | 6 (40) |
| 19.8 Gy in 11 fractions | 1 (7) |
| Second-line chemotherapy regimens | |
| Vincristine + irinotecan + temozolomide | 21 (64) |
| Nimotuzumab | 6 (18) |
| Temozolomide | 6 (18) |